Novo Nordisk to Invest €2.1 billion in Expansion of Production Facilities in Chartres, France

Specifications:

Name:

Novo Nordisk to Invest €2.1 billion in Expansion of Production Facilities in Chartres, France

Location:

Chartres, France

Company:

Novo Nordisk

Estimated Cost:

€2.1 billion

Source:

https://www.novonordisk.com/

Introduction:

Novo Nordisk announced the investment of more than 16 billion Danish kroner (2.1 billion euros) to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Features:

The investment will significantly increase the capacity of the manufacturing site, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory. The investment, which includes capacity for GLP-1 products, will increase Novo Nordisk’s ability to meet future demands for innovative medicines.

The new facilities will more than double the footprint of the site. The facility will be designed as a multi-product facility to accommodate current and future processes and displaying state-of-the-art technology and working environment. As a future-proof and cost-effective facility, the construction will focus on delivering the highest quality to patients globally in an efficient and environmentally sustainable way.

The construction projects have now been initiated and will gradually be finalised from 2026 to 2028. The investment is expected to create more than 500 new jobs to run production activities 24/7 when the construction is completed, and the facilities are finalised. During the construction phase, up to 2,000 external employees will be employed.